

## CPSA – Where Technology and Solutions Meet

### 1998 Program Chairs

Mike S. Lee, Milestone Development Services  
Edward H. Kerns, Milestone Development Services

#### Plenary Lecture

Richard A. Yost, University of Florida  
*Pushing the Bioanalytical Envelope with Ion Trap Mass Spectrometry*

#### Featured Symposia and Roundtables

Metabolism || Analysis Strategies || Emerging Technologies || Biomolecular Separations || Automation || Combinatorial Chemistry || Impurities, Degradants and Natural Products || Recruiting, Developing and Motivating Scientists || Outsourcing || Biomolecule Analysis || Pharmacokinetics

### 1999 Program Chair

Mike S. Lee, Milestone Development Services

#### Plenary Lecture

Richard M. Caprioli, Vanderbilt University  
*Mass Spectrometry Imaging: A Tool for the 21<sup>st</sup> Century*

#### Featured Symposia and Roundtables

Proteomics || Sample Preparation || Combinatorial Chemistry || Automation || Fast Chromatography || Lead Optimization || Accelerated Drug Discovery || Using Dedicated Instruments || Well Characterized Biologics || Information Management || Lead Identification || Emerging Technologies

### 2000 Program Chair

Todd A. Gillespie, Eli Lilly and Company

#### Plenary Lecture

John R. Yates, The Scripps Research Institute  
*Proteomics Using Multidimensional Chromatography and Tandem Mass Spectrometry*

#### Featured Symposia and Roundtables

New Technologies and Approaches for Drug Metabolism || Sample Preparation || Chromatography || Structure and Purity Determination: How Much and When? || How to Demo/Purchase an LC/MS Instrument: Experiences and Perspectives || Drug Discovery in the Post-Genome Era: Proteomics/Genomics || Predictive Models for Lead Optimization and Selection || Mass Spectrometry || Data Management || Mass Spectrometry in the QC Laboratory: Are We Ready? || Purification Systems for Combinatorial Chemistry || Is LC/TOF a Viable Bioanalytical Tool? || Data Management and Manipulation || Drugability High Throughput Screening || In Vitro Methods || New Technologies and Future Trends for High Throughput

**2001 Program Chair**

Robyn A. Rourick, DuPont Pharmaceuticals

**Plenary Lecture**

Donald G. Robertson, Pfizer

*Of Mice and Magnets: Metabonomic Technology as a Tool for Rapid-Throughput Toxicity Evaluation*

**Featured Symposia and Roundtables**

Structure Profiling || Sample Preparation & Chromatography || High Throughput Synthesis Support: Open-Access Applications and Formats || The Emerging Future/Role of Proteomics in Drug Discovery || Pharmaceutical Property Profiling: Metrics and Implementation || Mass Spectrometry & Data Management || Hyphenated NMR Methods in Pharmaceutical R&D || Strategies for Overcoming the Bottlenecks in Assessing Toxicity || Predictive Models for Drug Discovery Screening || Technology Transfer: Drug Discovery to Drug Development Perspectives || Emerging Technologies

**2002 Program Chair**

Kenneth L. Morand, Procter & Gamble Pharmaceuticals

**Plenary Lecture**

Joseph A. DiMasi, Tufts Center for the Study of Drug Development

*Trends in the Economics of Pharmaceutical Innovation: Cost, Time, and Risk*

**Featured Symposia and Roundtables**

Genomics/Post-Genomics Trends || Instrumentation for Protein Characterization: Emerging Trends in Proteomic Analysis || Metabonomics || Advances in Microfluidics Technology || The Value of the Corporate Compound Collection: Protecting Your Investment || Preclinical Lead Optimization: Are We Making A Difference? || Emerging Technologies for Drug Discovery & Development || Data Management in a High-Throughput Analysis Environment || Why Does Method Development Take So Long? || In-Source, Out-Source: What Do Pharmaceutical Companies Do for Bioanalytical Support? || Crystal City Guideline Review

**2003 Program Chair**

Nigel J. Clarke, ActivX Biosciences

**Plenary Lecture**

Simon J. Gaskell, The University of Manchester Institute of Science and Technology

*The Multi-Dimensionality of the Proteome*

**Featured Symposia and Roundtables**

Functional Proteomics: Quantitation || Discovery and Validation of Proteomic Biomarkers for Drug Development || Functional Proteomics: Relationships || Bioinformatics for Proteomics || Lead Optimization || Reactive Xenobiotic Intermediates || Compound Library Analysis and Profiling || Conversion of Data to Information: Dissemination of Information to Drive Therapeutic Area Projects || Recent Regulatory Guidance: Bioanalytical Impact on Drug Development || Bioanalytical LC/MS/MS Methods: Perspectives and Lessons Learned || Research Informatics in Drug Development

## 2004 Program Chairs

Steven A. Hofstadler, Ibis Therapeutics  
Mark Sanders, Bristol-Myers Squibb

### Plenary Lecture

Richard D. Smith, Pacific Northwest National Laboratory  
*Quantitative and Ultra-Sensitive High Throughput Proteomics*

### Keynote Lectures

David H. Russell, Texas A&M University  
*Molecular Imaging Using MALDI and Ion Mobility-Mass Spectrometry: A New Paradigm for Proteomics*

Richard Beger, Food & Drug Administration  
*Metabolic Profiles of Drug Toxicity and Disease*

### Featured Symposia and Roundtables

Biomarkers: Initiatives, Perspectives & Approaches || How Do We Set Priorities in Drug Discovery & Development? || Outsourcing Trends: Emerging Business Models & Overseas Partners || High Throughput Analysis & Information Management Strategies || Current Strategies & Preferences for Metabolite Identification || Biomarker Discovery || High Throughput ADME & Pharmaceutical Property Profiling || Tissue Imaging: Localization of Drugs & Metabolites || Biomarker Evaluation || Emerging Technologies & Applications

## 2005 Program Chair

Bradley L. Ackermann, Eli Lilly and Company

### Plenary Lecture

R. Graham Cooks, Purdue University  
*Enabling Biology Through Analytical Innovation: Tissue Imaging in the Ambient Environment Using DESI Mass Spectrometry*

### Keynote Lectures

Yining Zhao, Pfizer  
*Modern Separation Science: Quo Vadis? – The Pursuit of Higher Resolution and Higher Speed Separation in Drug Discovery and Development*

John T. Stults, Predicant Biosciences  
*Discovery and Clinical Validation of Serum Biomarkers for Disease Diagnosis*

### Distinguished Analytical Scientist Award

Mark J. Cole, Pfizer

### Featured Symposia and Roundtables

Biomarkers: Proteomics Strategies || Metabolite Identification: Emerging Strategies to Make Better Use of Time & Resources || Chromatography || Bioanalytical: Current Strategies || Pharmaceutical Properties: Compound Library Analysis & Profiling || Biomarkers: Metabonomics Strategies || Bioanalytical: Driving Technologies & Methodologies || Pharmaceutical Properties: HT ADME || Biomarkers: New Technologies & Approaches || NMR Analysis: Emerging Analysis Strategies & Methodologies || Bioanalytical: Exploratory Technologies

## 2006 Program Chair

Jing-Tao Wu, Millennium Pharmaceuticals

### Plenary Lecture

Mark L. Powell, Bristol-Myers Squibb

*Analytical Chemistry: A Changing Paradigm of Advanced Process Models, Tools and Technologies in R&D*

### Keynote Lectures

Richard C. King, Merck Research Laboratories

*Ion Formation from Complex Solutions: Understanding Matrix Effects and Ionization Suppression*

David M. Lubman, University of Michigan

*Markers of Cancer Using a Liquid Proteomics Approach*

### Distinguished Analytical Scientist Award

Richard C. King, Merck Research Laboratories

### Featured Symposia and Roundtables

Proteins and Early Biology || Discovery Strategy: The Minimalist Approach Versus the Fail Faster Model || Predictive Toxicology || Measurement of Drug in Clinical Development || Pharmaceutical Sciences - Analytical New Strategies || Chemistry in Drug Discovery || The Unsolved Mystery: Reactive Metabolites || AAPS/FDA Bioanalytical Workshop: Take Home Messages and Implementation || Clinical Development – Measurement of Drug Effects || Biomarkers in Drug Discovery || Pharmaceutical Sciences - Analytical New Technologies || Emerging New Technologies || Pharmacokinetics & Pharmacodynamics

## 2007 Program Chair

Nalini Sadagopan, Pfizer

### Plenary Lecture

Jonathan L. Josephs, Bristol-Myers Squibb

*Why Can't We All Just Get Along: An Integrated Approach to Solving ADME Issues*

### Keynote Lectures

Bradley L. Ackermann, Eli Lilly and Company

*From Bioanalytical to Biomarkers - Using Quantitative Mass Spectrometry to Address Biological Bottlenecks*

Liang Li, University of Alberta

*Development and Applications of Improved Sample Handling and LC-MS Techniques for Comprehensive Proteome and Metabolome Analysis*

### Distinguished Analytical Scientist Award

Bradley L. Ackermann, Eli Lilly and Company

### Featured Symposia and Roundtables

Biomarkers in Preclinical Development || Bioanalytical CRO – Assay Transfers || Proteo-Metabonomic Strategies in Drug Development || High Throughput Approaches – Fast Separations || Biologics || Metabolomics and Metabonomics || Omics Technologies || New Technologies and Trends in Bioanalysis || Drug Metabolism in Preclinical and Clinical Development || Driving Pharmaceutical Quality || Biomarkers in Clinical Development || ADME Strategies: Past, Present and Future

## 2008 Program Chair

Lucinda Cohen, Merck Research Laboratories

### Plenary Lecture

David M. Hercules, Vanderbilt University

*Mass Spectrometry of Synthetic Polymers: Some Challenges and Some Successes*

### Keynote Lectures

Thomas R. Covey, MDS Analytical Technologies

*Where Can We Go From Here? An Assessment of the Limits to Sensitivity of Electrospray and MALDI*

J. Michael Ramsey, University of North Carolina

*Protein and Peptide Analysis Using Microfabricated Fluidic Devices*

### Distinguished Analytical Scientist Award

Thomas R. Covey, MDS Analytical Technologies

### Featured Symposia and Roundtables

Excellence in Bioanalysis Through Automation || Insourcing, Outsourcing and Offshoring || Emerging Analytical Tools for Biologics || "Nano" Applications to Small Molecule Analysis || Biomarkers in Preclinical and Clinical Development || Adding Another Dimension to the Quantitation of Peptides and Proteins || Leveraging Analytical Chemistry for Drug Metabolism Studies || Operational Excellence through IT and Hardware Solutions || Approaches to Overcome Poor Pharmacokinetic Properties for Lead Compounds || Is There Life Beyond LC/MS?

## 2009 Program Chair

Kevin P. Bateman, Merck Frosst Canada

### Plenary Lecture

Ian Jardine, Thermo Fisher Scientific

*The Impact of High-Performance Mass Spectrometry on Biology Research*

### Keynote Lectures

Walter A. Korfmacher, Schering-Plough Research Institute

*Using Mass Spectrometry in Drug Discovery: Past, Present and Future*

Thomas A. Baillie, University of Washington

*The Impact of Mass Spectrometry in Pharmaceutical Lead Optimization – Studies on Metabolic Activation*

### Distinguished Analytical Scientist Award

Walter A. Korfmacher, Schering-Plough Research Institute

### Featured Symposia and Roundtables

High Performance Workflows: Emerging Applications for Simultaneous Qualitative-Quantitative Analysis || Why Biomarkers for Toxicology and Clinical Diagnostics Fail or Don't Have Broader Acceptance? || Small Interfering RNA and Gene Silencing: Emerging Opportunities for Analysis in Drug Discovery and the Potential of a Bioanalytical Equivalent || Small Molecule Biomarker Assay Development and Validation || Protein Based Biomarkers || Tools for Understanding Biology Through Analysis || Toxicity Markers || Peptide and Protein Quantitation: Are Trypsin and MRM Sufficient? || High Throughput Quantitation: Going Faster by Going Faster and Going Slower || Maintaining Our Innovative Fitness During Times of Transition